Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients
Abstract
Fluoroquinolones (levofloxacin (Lfx) and moxifloxacin) belong to the class A drugs for treating multidrug-resistant (MDR) tuberculosis (TB), which is characterised by resistance to both rifampicin and isoniazid [1]. The drugs have become a mainstay in both longer and shorter MDR-TB regimens, as well as isoniazid resistance [1, 2]. Despite this potential, currently used doses have become a major concern due to subtherapeutic concentrations achieved, leading to acquired drug resistance [3–5]. 50% of MDR-TB patients with higher MICs do not have enough Lfx exposure with currently prescribed once-daily dosing of 750–1000 mg. Therefore, it is suggested that MDR-TB patients should receive higher 1250–1500 mg Lfx dosages. http://ow.ly/ZQsN30nuNBx
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.